Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Tanezumab ELISA Kit

Catalog #:   KDB91701 Specific References (50) DATASHEET
Applications: Used for the quantitative determination of Tanezumab concentration in serum and plasma.
Sample type: Plasma, Serum
Sensitivity: 128.01 ng/mL
Range: 156.25 - 10,000 ng/mL
Overview

Catalog No.

KDB91701

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human NGF has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Tanezumab in the sample competitively binds to the pre-coated protein with biotin-labeled Tanezumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Tanezumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Tanezumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

156.25 - 10,000 ng/mL

Sensitivity

128.01 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

 

Intra-Assay Precision

Inter-Assay Precision

Sample

1

2

3

1

2

3

n

16

16

16

24

24

24

Mean (ng/mL)

4861.0

1011.8

253.3

5343.4

1264.1

293.1

Standard deviation

218.8

64.1

29.0

523.4

167.7

51.5

CV (%)

4.5

6.3

11.4

9.8

13.3

17.6

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.

Alternative Names

PF-04383119, RN624, CAS: 880266-57-9

Background

Tanezumab (RN624) is a recombinant humanized anti- nerve growth factor (NGF) monoclonal antibody (IgG2 type) that works by inhibiting the binding of NGF to its receptors. It was developed by Pfizer as a treatment for pain.

Data Image
  • Experiment Example
    CALCULATION OF RESULTS
    Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. Do not include the blank in the standard curve. The data may be linearized by plotting the log of the Tanezumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
References

Associations between testosterone and knee and hand osteoarthritis among males and females from the general population., PMID:40221126

Metabolic syndrome, radiographic osteoarthritis progression and chronic pain of the knee among men and women from the general population: The Rotterdam study., PMID:39288696

Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs., PMID:38885831

The Polyanalgesic Consensus Conference (PACC)®: Intrathecal Drug Delivery Guidance on Safety and Therapy Optimization When Treating Chronic Noncancer Pain., PMID:38752946

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis., PMID:38650049

Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients., PMID:37954824

Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab., PMID:37652258

Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor., PMID:37470295

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis., PMID:37460782

A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis., PMID:37343145

Role of imaging for eligibility and safety of a-NGF clinical trials., PMID:37284331

Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis: A Mediation-Modeling Approach., PMID:36806283

The Current Role of Disease-modifying Osteoarthritis Drugs., PMID:36793668

Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials., PMID:36621827

[Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus]., PMID:36594136

Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials., PMID:36542785

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab., PMID:36474952

A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis., PMID:36301512

Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression., PMID:36285300

Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis., PMID:38343426

Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain., PMID:36038003

Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials., PMID:35980115

Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial., PMID:35962939

Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis., PMID:35960482

Trends of Dispensed Opioids in Catalonia, Spain, 2007-19: A Population-Based Cohort Study of Over 5 Million Individuals., PMID:35754470

Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis., PMID:35619987

Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies., PMID:35538185

Efficacy and Safety of Anti-Nerve Growth Factor Antibody Therapy for Hip and Knee Osteoarthritis: A Meta-analysis., PMID:35494494

Gout and Hospital Admission for Ambulatory Care-Sensitive Conditions: Risks and Trajectories., PMID:35428711

Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model., PMID:35417079

Tanezumab for the treatment of osteoarthritis pain., PMID:35412532

Comorbidities in osteoarthritis (ComOA): a combined cross-sectional, case-control and cohort study using large electronic health records in four European countries., PMID:35387809

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study., PMID:35351194

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets., PMID:35295464

[Osteoarthritis: what's new?]., PMID:35291041

WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee., PMID:35232805

Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis., PMID:35217440

Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2)., PMID:35121640

Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain., PMID:35112378

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis., PMID:35105318

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials., PMID:35069811

Effectiveness of Various Dosages and Administration Methods of Tanezumab for the Treatment of Pain in Knee and Hip Osteoarthritis: a Network Meta-Analysis., PMID:34819241

Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review., PMID:34807432

Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study., PMID:34786956

Different Drugs for the Treatment of Painful Diabetic Peripheral Neuropathy: A Meta-Analysis., PMID:34777192

Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes., PMID:34665205

Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor., PMID:34627999

Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials., PMID:34626502

Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials., PMID:34608021

Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis., PMID:34606077

Datasheet

Document Download

Tanezumab ELISA Kit.pdf

 

$ 1128
Product specifications
96 T 1128

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Tanezumab ELISA Kit [KDB91701]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only